Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ERS congress

- PMLiVE

Boehringer launches COPD patient consultation app for HCPs

Extends reach of the calculator tools on its COPD Exchange website

- PMLiVE

IQWiG knocks back Almirall’s Eklira

Decides added benefit of COPD drug is not proven

- PMLiVE

AstraZeneca removes R&D and commercial heads

Pascal Soriot's leadership shake-up will see Martin Mackay and Tony Zook leave

- PMLiVE

GSK and Theravance file COPD combo for EU approval

Filing for LAMA/LABA combination comes shortly after US submission

Novartis building

Novartis parts with Eisai to go it alone with COPD drugs

Ends co-promotion agreement for Onbrez, Seebri and QVA149

- PMLiVE

AstraZeneca wins stay on Crestor generics in US

Appeals court upholds earlier ruling to validate patent until 2016

- PMLiVE

AstraZeneca’s fostamatinib fails to match Humira in RA

Inferiority to Abbott’s drug dents commercial prospects

Forest Labs launches COPD drug Tudorza in US

Enters a market dominated by Boehringer and Pfizer's Spiriva and GSK's Advair

- PMLiVE

AstraZeneca antitrust fine upheld by European Court of Justice

Lessons for pharma as landmark ruling stands

- PMLiVE

Boehringer launches COPD awareness drive in Japan

Social media campaign will target male smokers’ wives and daughters

- PMLiVE

EU approval for AZ/BMS’ first-in-class diabetes drug Forxiga

First SGLT2 inhibitor to be approved for marketing anywhere in the world

- PMLiVE

WHO launches framework to monitor non-communicable diseases

Will measure success of efforts to reduce rates of cancer, diabetes, lung conditions and heart disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links